Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
Public ClinicalTrials.gov record NCT01522651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the effect of ranolazine and of low-dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment. AFB is defined as the total time a participant is in atrial tachycardia/atrial fibrillation (AT/AF) expressed as a percentage of total recording time.
Study identification
- NCT ID
- NCT01522651
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 134 participants
Conditions and interventions
Conditions
Interventions
- Ranolazine Drug
- Dronedarone Drug
- Ranolazine placebo Drug
- Dronedarone placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 23, 2012
- Primary completion
- Mar 9, 2014
- Completion
- Mar 9, 2014
- Last update posted
- Nov 5, 2020
2012 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site | Beverly Hills | California | 90211 | — |
| Investigational Site | Newport Beach | California | 92663 | — |
| Investigational Site | San Francisco | California | 94143 | — |
| Investigational Site | Aurora | Colorado | 80012 | — |
| Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| Investigational Site | Lakeland | Florida | 33805 | — |
| Investigational Site | Takoma Park | Maryland | 20912 | — |
| Investigational Site | Towson | Maryland | 21204 | — |
| Investigational Site | Utica | New York | 13501 | — |
| Investigational Site | Cleveland | Ohio | 44106 | — |
| Investigational Site | Warwick | Rhode Island | 02886 | — |
| Investigational Site | Houston | Texas | 77030 | — |
| Investigational Site | Murray | Utah | 84107 | — |
| Investigational Site | Seattle | Washington | 98122 | — |
| Investigational Site | Wausau | Wisconsin | 54401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01522651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2020 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01522651 live on ClinicalTrials.gov.